- Home
- ECO vs ARDX Comparison
ECO vs ARDX Comparison
Compare ECO & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECO
- ARDX
- Stock Information
- Founded
- ECO 2018
- ARDX 2007
- Country
- ECO Greece
- ARDX United States
- Employees
- ECO N/A
- ARDX N/A
- Industry
- ECO
- ARDX Biotechnology: Pharmaceutical Preparations
- Sector
- ECO
- ARDX Health Care
- Exchange
- ECO Nasdaq
- ARDX Nasdaq
- Market Cap
- ECO 878.3M
- ARDX 882.9M
- IPO Year
- ECO N/A
- ARDX 2014
- Fundamental
- Price
- ECO $28.29
- ARDX $5.18
- Analyst Decision
- ECO Strong Buy
- ARDX Strong Buy
- Analyst Count
- ECO 2
- ARDX 9
- Target Price
- ECO $34.50
- ARDX $10.50
- AVG Volume (30 Days)
- ECO 137.2K
- ARDX 3.0M
- Earning Date
- ECO 11-07-2025
- ARDX 10-30-2025
- Dividend Yield
- ECO 6.43%
- ARDX N/A
- EPS Growth
- ECO N/A
- ARDX N/A
- EPS
- ECO 2.09
- ARDX N/A
- Revenue
- ECO $344,213,634.00
- ARDX $386,146,000.00
- Revenue This Year
- ECO N/A
- ARDX $17.34
- Revenue Next Year
- ECO $10.10
- ARDX $27.08
- P/E Ratio
- ECO $13.55
- ARDX N/A
- Revenue Growth
- ECO N/A
- ARDX 83.88
- 52 Week Low
- ECO $17.91
- ARDX $3.21
- 52 Week High
- ECO $35.64
- ARDX $6.84
- Technical
- Relative Strength Index (RSI)
- ECO 46.45
- ARDX 31.09
- Support Level
- ECO $28.34
- ARDX $5.24
- Resistance Level
- ECO $29.55
- ARDX $6.62
- Average True Range (ATR)
- ECO 0.62
- ARDX 0.18
- MACD
- ECO -0.28
- ARDX -0.15
- Stochastic Oscillator
- ECO 18.71
- ARDX 5.60
About ECO Okeanis Eco Tankers Corp.
Okeanis Eco Tankers Corp owns and operates tanker vessels in Greece. The business of the company is to own, charter out, and operate tanker vessels. The company owns, through its vessel-owning subsidiaries, a fleet of around seven tanker vessels and has around eight tanker vessels on order. The sailing fleet consists of around six modern Suezmax tankers and eight VLCC tankers.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.